Adding Venetoclax to Daratumumab and Dexamethasone in RRMM

EP: 1.Treatment Options for Patients With MM at First Relapse

EP: 2.A Role for Bispecific Antibodies in R/R MM: Data From MonumenTAL-1 and MajesTEC-1 Studies

EP: 3.How Will Bispecific Antibodies Fit Into the Multiple Myeloma Treatment Paradigm?

EP: 4.Key Takeaways From the ASH 2021 Meeting on Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

EP: 5.Transplant-Eligible NDMM: Updated Results of the GRIFFIN Study

EP: 6.Transplant-Eligible NDMM: Results From the MASTER Study

EP: 7.Triplet or Quadruplet Therapy in Transplant-Ineligible NDMM

EP: 8.Daratumumab in NDMM: Subcutaneous vs IV Formulation

EP: 9.Relapsed/Refractory MM: Results From the BELLINI Study

Now Viewing

EP: 10.Adding Venetoclax to Daratumumab and Dexamethasone in RRMM

EP: 11.ASH 2021: Additional Highlights in Multiple Myeloma

EP: 12.ASH 2021: Key Takeaways for Clinical Practice in Multiple Myeloma

Transcript:

Saad Z. Usmani, MD: The combination of daratumumab with venetoclax and dexamethasone has been evaluated and reported on previously, primarily focusing on translocation (11;14) relapsed/refractory multiple myeloma. The initial dose-escalation study has previously been presented showing that this combination is very active for patients with translocation (11;14). At ASH [American Society of Hematology annual meeting] this year [2021], my colleague Jonathan Kaufman, [MD,] from Emory University had reported on the third part, which was a randomized phase 2 study part comparing venetoclax, daratumumab, dexamethasone to daratumumab, bortezomib, dexamethasone in patients with translocation (11;14). What he showed was a clear benefit in favor of the venetoclax, daratumumab, dexamethasone combination.

Now, this is a small randomized phase 2 study with a highly selected translocation (11;14) population. The safety profile looked tolerable. The responses were very high in favor of the venetoclax, daratumumab, dexamethasone combination. At the dose of 400 mg, I think the response rates were somewhere in the mid-70% range, whereas with the 800 mg dose of venetoclax, the responses were almost 100%. I’m excited about these data. I think we just need to see long-term follow-up to see if these responses are translating into PFS [progression-free survival] benefit for this patient population.

Transcript edited for clarity.